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Abstract: Vitamin D induces a diverse range of biological effects, including important functions
in bone health, calcium homeostasis and, more recently, on immune function. The role of vitamin
D during infection is of particular interest given data from epidemiological studies suggesting
that vitamin D deficiency is associated with an increased risk of infection. Vitamin D has diverse
immunomodulatory functions, although its role during bacterial infection remains unclear. In this
study, we examined the effects of 1,25(OH)2D3, the active metabolite of vitamin D, on peripheral
blood mononuclear cells (PBMCs) and purified immune cell subsets isolated from healthy adults
following stimulation with the bacterial ligands heat-killed pneumococcal serotype 19F (HK19F)
and lipopolysaccharide (LPS). We found that 1,25(OH)2D3 significantly reduced pro-inflammatory
cytokines TNF-α, IFN-γ, and IL-1β as well as the chemokine IL-8 for both ligands (three- to
53-fold), while anti-inflammatory IL-10 was increased (two-fold, p = 0.016) in HK19F-stimulated
monocytes. Levels of HK19F-specific IFN-γ were significantly higher (11.7-fold, p = 0.038) in vitamin
D-insufficient adults (<50 nmol/L) compared to sufficient adults (>50 nmol/L). Vitamin D also shifted
the pro-inflammatory/anti-inflammatory balance towards an anti-inflammatory phenotype and
increased the CD14 expression on monocytes (p = 0.008) in response to LPS but not HK19F stimulation.
These results suggest that 1,25(OH)2D3 may be an important regulator of the inflammatory response
and supports further in vivo and clinical studies to confirm the potential benefits of vitamin D in
this context.
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1. Introduction
Global burden of disease data estimates that infections are responsible for ~3 million deaths of
children under five years of age per year [1]. Bacterial infections comprise a significant proportion of
this, with Gram-positive and Gram-negative bacteria such as Streptococcus pneumoniae, Escherichia coli,
and Salmonella typhi the leading candidates [2]. Exposure to these organisms can be extremely high,
especially in low-income country settings, leading to persistent activation of host inflammatory
responses. Local immune responses in the early stages of infection, such as the recruitment of
neutrophils and release of pro-inflammatory cytokines (IL-1β, TNF-α) play an important role in
pathogen clearance. However, failure to clear the pathogen may lead to persistent infections and
excessive inflammation, leading to serious diseases, such as pneumonia, meningitis, and diarrheal
illness [2,3].
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An increasing number of epidemiological studies have demonstrated a strong association between
low levels of hydroxyvitamin D3 [25(OH)D3], the inactive precursor of vitamin D, and an increased
risk of respiratory infections [4,5], especially in countries with low exposure to sunlight [6–8], while
the data is less clear for enteric infections. In Mongolia, the high burden of pneumonia has been linked
to vitamin D deficiency, and supplementation in young children protected against acute respiratory
infection [9]. However, a recent review of randomized controlled trials of vitamin D supplementation
for the prevention of respiratory infections was inconclusive [10].
Vitamin D has diverse immunomodulatory functions. The vitamin D receptor (VDR) is widely
expressed on all immune cellular subsets and VDR ligation by vitamin D results in activation of
key innate immune cells such as monocytes, macrophages, and neutrophils leading to enhanced
chemotactic, phagocytic, and bactericidal activities [11–13]. The VDR binds 1,25(OH)2D3 with a much
greater affinity than 25(OH)D3 [14]. Vitamin D also modulates the expression of Toll-like receptors
(TLRs) [15] and the co-receptor CD14 [16] on important innate immune cells, promotes the conversion
of 25(OH)D3 to the active form (dihydroxyvitamin D3—1,25(OH)2D3), and induces production
of anti-microbial peptides, such as cathelicidin, which inhibit the growth of both Gram-positive
and Gram-negative bacteria [17,18]. Vitamin D also promotes anti-inflammatory effects through
up-regulation of IL-10 [19]. Therefore, it is likely that vitamin D has a critical role in modulating
bacterial-specific inflammatory responses.
Given the paucity of data in relation to the immunomodulatory effects and possible protection
elicited by vitamin D, we hypothesized that the active form of vitamin D, 1,25(OH)2D3, modulates
critical host responses important in host protection against Gram-positive and Gram-negative infection.
2. Materials and Methods
2.1. Study Samples
Samples were collected from healthy adults (n = 19) aged 19–64 (mean = 30) years old from
the Royal Children’s Hospital, Melbourne, and comprised six males and 13 females. The study was
approved by the Royal Children’s Hospital Human Research Ethics Committee and all participants
were recruited following informed consent.
2.2. Materials
The active metabolite of vitamin D3, 1,25(OH)2D3, and the inactive preform, 25(OH)D3, were
purchased from Tocris Bioscience (Bristol, UK). Purified lipopolysaccharide (LPS) from Escherichia coli
serotype 055:B5 was purchased from Sigma-Aldrich (St. Louis, MO, USA). Heat-killed pneumococcal
bacteria serotype 19F (HK19F; reference strain originally obtained from the University of Alabama)
was prepared by harvesting the mid-log phase of the bacterial culture and incubating in a water bath at
80 ◦C for 60 min. The bacterial concentration was determined before and after heat-killing by plating
on horse blood agar plates. The HK19F was stored in aliquots at −80 ◦C prior to use, and the same
batch was used throughout the study. Neutrophils were derived by stimulation of a HL-60 cell line
(ATCC® CCL-240™, Manassas, VA, USA) with 100 mM N,N-dimethylformamide for five days.
2.3. Cell Culture
Peripheral blood mononuclear cells (PBMCs) were isolated from heparinised whole blood using
Lymphoprep (Axis-Shield, Oslo, Norway). CD14+ monocytes were isolated by negative selection
using antibody conjugated magnetic beads (Stemcell Technologies, Tullamarine, VIC, Australia).
The purity of the isolated CD14+ monocytes was 82%, consistent with manufacturer’s guidelines.
PBMCs were cultured in duplicate using 24-well cell-culture plates (Thermo Scientific, Roskilde,
Denmark). One million PBMCs/mL were pre-treated with either 100 nmol/L 1,25(OH)2D3, 500 nmol/L
25(OH)D3 or vehicle (RPMI-FBS medium containing 0.08% (v/v) ethanol; untreated) and incubated for
4 h at 37 ◦C in 5% CO2. Pre-treated PBMCs were then stimulated for 24 h with either LPS (1 µg/mL),
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HK19F (HK19F:PBMC ratio of 50:1) or unstimulated (RPMI-FBS). Similar experiments were performed
for isolated CD14+ monocytes which were cultured in duplicate at 1.5× 105 cells/well in round-bottom
96-well culture plates (Greiner Bio-one, Frickenhausen, Germany). Supernatants were collected and
stored at −80 ◦C until cytokine analysis.
2.4. Plasma 25(OH)D Measurement
Plasma samples from healthy volunteers were sent to the Peter MacCallum Cancer Institute,
Melbourne, Australia to determine their 25(OH)D status. Plasma 25(OH)D concentrations were
measured by a chemiluminescence delayed, one-step assay (Abbott Diagnostics, Wiesbaden, Germany)
on the Abbott Architect ci4100 analyser. Three controls, Liquichek Speciality Control 1, 2, and 3
(Bio-Rad, Irvine, CA, USA) were included in all assays.
2.5. Measurement of Cytokines
Levels of TNF-α, IFN-γ, IL-1β, IL-10, IL-4, IL-8, and IL-17A in cultured supernatants from PBMCs
and CD14+ monocytes were measured using a commercial Milliplex human cytokine multiplex bead array
method, as per the manufacturer’s instructions (Milliplex; Millipore Corporation, Billerica, MA, USA).
2.6. Flow Cytometry
To identify specific immune cell subsets in PBMCs following 1,25(OH)2D3 treatment, the cells
were stained with fluorescently-conjugated monoclonal antibodies CD4-BUV737, CD14-BV605,
and CD3-BV510 (BD Bioscience; San Diego, CA, USA). Compensation bead particles were used
to account for the spectral overlap (BD Bioscience, San Diego, CA, USA) above and analyzed using the
BD LSRII flow cytometer. Unstained PBMCs were used as a control and a minimum of 20,000 events
were analysed per sample gated on live, single cell lymphocyte gate based on FFS and SSC, where the
expression of the cell surface molecules were evaluated using MFI values using BD FACSDiva 8.0.1
software (Becton, Dickinson and Company, Franklin Lakes, NJ, USA).
2.7. Neutrophil Migration Assay
Neutrophils cultured in a 24-well plate at a concentration of 4 × 106 cells/mL. Cells were either
pre-treated with 100 nmol/L of 1,25(OH)2D3 or left untreated and incubated at 37 ◦C, 5% CO2 for 1 h.
Transwell plates (6.5 mm Transwell® with a 8.0 µm pore polycarbonate membrane insert, Corning, NY,
USA) were used to test neutrophil migration. The bottom chamber contained 400 µL of 5.2 mg/mL
casein (as a chemoattractant) and the membrane was submerged in casein for 30 min at 37 ◦C and
5% CO2. Neutrophils (5 × 104 cells) were added to the top chamber and incubated at 37 ◦C and 5%
CO2 for 1 h. Following this, the top chambers were removed and the number of migrated cells were
determined by cell counting using a haemocytometer.
2.8. Statistics
Cytokine data was presented as mean ± standard error of the mean (SEM). Flow cytometry
and cytokine ratio data were presented as mean fold change ± SEM. Graphical presentation and
statistical analysis were calculated using GraphPad Prism 6 software (Graphpad Software Inc., La Jolla,
CA, USA). Comparison of cytokine data and ratios between treated groups (with 1,25(OH)2D3 or
25(OH)D3) and untreated groups were done using a non-parametric paired Wilcoxon sign-rank test.
Flow cytometry data was analysed by Mann-Whitney U test. An unpaired Student’s t-test was used
to compare cytokine levels between individuals with an insufficient (<50 nmol/L) and sufficient
(>50 nmol/L) 25(OH)D status. Spearman’s correlation test was performed for plasma 25(OH)D and
cytokine correlations. All tests were two-tailed with a p-value < 0.05 considered significant.
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3. Results
3.1. 1,25(OH)2D3 Suppresses Pro-Inflammatory Cytokines in PBMCs and CD14+ Monocytes
The cytokine response in PBMCs pre-treated with 1,25(OH)2D3 and stimulated with HK19F is
shown in Figure 1, and shows a significant reduction in TNF-α (3.7-fold, p = 0.0002) and IFN-γ
(53-fold, p = 0.0002) compared to untreated, HK19F-stimulated cells. IL-1β (p = 0.04) and IL-8
(p = 0.02) were also reduced by 1,25(OH)2D3 while IL-10 was unaffected by 1,25(OH)2D3 or 25(OH)D3.
In HK19F-stimulated CD14+ monocytes 1,25(OH)2D3 significantly decreased TNF-α (four-fold,
p = 0.031) but increased IL-10 (two-fold, p = 0.016) compared to untreated HK19F-stimulated CD14+
monocytes; no significant differences were observed for IFN-γ, IL-1β, or IL-8 levels. Negligible
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Figure 1. Cytokine responses of HK19F-stimulated PB Cs and CD14+ monocytes. HK19F (1:50 ratio)
stimulated PBMCs and CD14+ monocytes pre-treated with 1,25(OH)2D3 or 25(OH)D3 for 4 h. Cytokine
concentrations (pg/mL) were measured in PBMC and CD14+ monocyte supernatants by multiplex
assay. Data shown represents Mean ± SEM for PBMCs (n = 13) and CD14+ monocytes (n = 7),
respectively. Significance was calculated using a paired Wilcoxon sign-rank test (black bar = untreated,
grey bar = 25(OH)D3 and white bar = 1,25(OH)2D3).
For PBMCs stimulated with LPS, TNF-α was significantly reduced by 3.6-fold and thr e-fold by
1,25(OH)2D3 and 25(OH)D3, respectively (p = 0.0002; Figure 2). The IFN-γ concentrations were also
significantly reduced in PBMCs tr ated with 25(OH)D3 (9-fold, p = 0.0002) and 1,25(OH)2D3 (five-fold,
p = 0.0002) compared to unt ted PBMCs. PBMCs treated with 25(OH)D3 signifi antly reduced IL-1β
(1.3-fold; p = 0.04), whereas PBMCs treated with 1,25(OH)2D3 significantly reduced IL-10 (1.2-fold,
p = 0.017) and IL-8 (1.5-fold; p = 0.001). In LPS-stimulated CD14+ onocytes, 1,25(OH)2D3 significantly
reduced TNF-α by 6.2-fold (p = 0.016) compared to untreated monocytes. The CD14+ monocytes
treated with 25(OH)D3 significantly reduced IL-1β by 2.7-fold (p = 0.031), but not for 1,25(OH)2D3.
There was no differential effect of 1,25(OH)2D3 or 25(OH)D3 when we compared the responses
after stratification by gender or age (data not shown), although the numbers of individuals for each of
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Figure  2.  Cytokine  responses  of  LPS‐stimulated  PBMCs  and  CD14+ monocytes.  LPS  (1  μg/mL) 
stimulated PBMCs and CD14+ monocytes pre‐treated with 1,25(OH)2D3 or 25(OH)D3 for 4 h. Cytokine 
concentrations (pg/mL) were measured  in PBMC and CD14+ monocyte supernatants by multiplex 
assay. Data shown represents  the mean ± SEM  for PBMCs  (n = 13) and CD14+ monocytes  (n = 7), 
respectively.  Significance was  calculated  using  a  paired Wilcoxon  sign‐ranked  test  (black  bar  = 
untreated, grey bar = 25(OH)D3 and white bar = 1,25(OH)2D3). 
We  investigated  whether  1,25(OH)2D3  or  25(OH)D3  modulates  the  pro‐inflammatory/anti‐












































































































































































Figure 2. Cytokine responses of LPS-stimulated PBMCs and CD14+ monocytes. LPS (1 µg/mL)
stimulated PBMCs and CD14+ monocytes pre-treated with 1,25(OH)2D3 or 25(OH)D3 for 4 h.
Cytokine concentrations (pg/mL) were measured in PBMC and CD14+ monocyte supernatants by
multiplex assay. Data shown represents the mean ± SEM for PBMCs (n = 13) and CD14+ monocytes
(n = 7), respectivel . Significance was calculated using a paired Wilcoxon sign-ranked test (black
bar = untreated, grey bar = 25(OH)D3 and white bar = 1,25(OH)2D3).
We investigated whether 1,25(OH)2D3 or 25(OH)D3 modulates the pro-inflammatory/
anti-inflammatory balance in response to TLR st mulation. In HK1 F-stimulated PBMCs, 1,25(OH)2D3
shifted the cytokine ratio towards an anti-inflammatory phenotype by 4.5-fold (p = 0.0002) for
TNF-α/IL-10 ratio, while for the IFN-γ/IL-10 ratio, this was decreased by 79-fold (p = 0.0002) (Figure 3).
For LPS-stimulated PBMCs, a similar effect was observed with 1,25(OH)2D3 in comparison to untreated
groups for TNF-α/IL-10 (p = 0.0002) and for IFN-γ/IL-10 (p = 0.0002) (Figure 4B). A shift towards an
anti-inflammatory phenotype was also observed for TNF-α/IL-10 ratio in HK19F (6.5-fold, p = 0.016)
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with  1,25(OH)2D3  or  25(OH)D3  for  4  h  and  stimulated with  (A) HK19F  or  (B) LPS. Data  shown 
represents  the mean ± SEM,  (n  =  13);  and  (C) CD14+ monocytes pre‐treated with  1,25(OH)2D3 or 
25(OH)D3 for 4 h and stimulated with HK19F or LPS. Data shown represents the mean ± SEM (n = 7). 
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Figure 3. Effect of 1,25(OH)2D3 on PBMCs and 14+ monocytes cytokine profile. PBMCs pre-treated
with 1,25(OH)2D3 or 25(OH)D3 for 4 h and stimulated with (A) HK19F or (B) LPS. Data shown
represents the mean ± SEM, (n = 13); and (C) CD14+ monocytes pre-treated with 1,25(OH)2D3 or
25(OH)D3 for 4 h and stimulated with HK19F or LPS. Data shown represents the mean ± SEM (n = 7).
Treatment groups were compared with untreated-stimulated groups only, with significance calculated
using a paired Wilcoxon sign-rank test.
3.2. 1,25(OH)2D3 Enh nces CD14 Expressi n in Sti lated PBMCs
We next examined the phenotype of key immune cell subsets in PBMCs following pre-treatment
with 1,25(OH)2D3 or 25(OH)D3. In unstimulated PBMCs, 1,25(OH)2D3 significantly increased CD4
expressi n on T cells (p = 0.008; Figure 4A) while for K19F, 1,25(OH)2D3 had no effect on CD4
or CD14 expression (Figure 4A,B). For LPS-stimulated PBMCs, expression of CD14 was increased
1.7-fold (p = 0.008) by treatment with 1,25(OH)2D3 and 25(OH)D3, but no change was observed for





with  1,25(OH)2D3  or  25(OH)D3  for  4  h  and  stimulated with  (A) HK19F  or  (B) LPS. Data  shown 
represents  the mean ± SEM,  (n  =  13);  and  (C) CD14+ monocytes pre‐tr ated with  1,25(OH)2D3 or 
25(OH)D3 for 4 h and sti ul t   it  HK19F or LPS. Data shown represents the mean ± SEM (n = 7). 











median  fluorescence  intensity (MFI)  for  (A) CD4 and  (B) CD14  in PBMCs (n = 5) pre‐treated with 































































Figure 4. Effects of 1,25(OH)2D3 pre-treatment on the immunophenotype of PBMCs. Fold change
in median fluorescence intensity (MFI) for (A) CD4 and (B) CD14 in PBMCs (n = 5) pre-treated with
1,25(OH)2D3 or 25(OH)D3 in comparison to unstimulated and HK19F/LPS stimulation. Data represents
the mean fold change ± SEM. Significance was calculated using a Mann-Whitney test (black bar =
untreated, grey bar = 25(OH)D3 and white bar = 1,25(OH)2D3).
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3.3. Plasma 25(OH)D Status Influences the Magnitude of Inflammatory Response
We then examined whether circulating vitamin D status affected cytokine responses following
HK19F and LPS stimulation. There was a similar 25(OH)D status between individuals used for each
experiment (Figure 5A). Although no significant correlation was found between plasma 25(OH)D levels
and IFN-γ concentrations (Figure 5B), individuals with 25(OH)D insufficiency (<50 nmol/L) exhibited
11.7-fold (p = 0.038) higher IFN-γ following HK19F stimulation compared to 25(OH)D sufficient
(>50 nmol/L) individuals (Figure 5C). There was a weak correlation between plasma 25(OH)D levels
and IL-10 concentrations (r = 0.2256; Figure 5B) with 25(OH)D sufficient individuals producing 1.5-fold
higher IL-10 levels following HK19F stimulation compared to 25(OH)D insufficient individuals,
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Figure 5. Influence of 25(OH)D status on inflammatory responses. (A) Data shows mean ± SEM
serum level of 25(OH)D in nmol/L for individuals in the LPS (n = 13) and HK19F (n = 13) conditions;
(B) correlation between plasma 25(OH)D status of healthy adults and levels of cytokines (IFN-γ and
IL-10) (n = 13). Correlation was calculated using Spearman’s test; and (C) correlation between cytokine
levels (IFN-γ and IL-10) and plasma 25(OH)D status of healthy adults with >50 nmol/L (n = 7) and
<50 nmol/L (n = 6). Significance was calculated using an unpaired t-test.
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3.4. 1,25(OH)2D3 Regulates Neutrophil Migration
We wanted to extend the above findings to examine the effect of 1,25(OH)2D3 on neutrophil
migration. Pre-treatment of neutrophils with 1,25(OH)2D3 showed a 57% reduction in neutrophil
migration in the absence of casein compared with untreated neutrophils (p = 0.022) (Figure 6).
In casein-stimulated cells, pre-treatment with 1,25(OH)2D3 reduced neutrophil migration by 46%
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Figure 6. Effects of 1,25(OH)2D3 pre-treatment on neutrophil migration. A total of 4 × 106 neutrophils
were pre-treated with 100 nmol/L of 1,25(OH)2D3 for 1 h followed by 1 h stimulation with 5.2 mg/mL
casein. Bars represent mean ± SEM (n = 7). Significance was calculated using a Student’s t-test (black
bar = untreated; white bar = 1,25(OH)2D3).
4. Discussion
Vitamin D has a number of biological effects, including the modulation of critical immune
res onses involved in host protection. To date, very few studies have investigated this aspect,
particularly in the context of bacterial infection. We investigated the effects of 1,25(OH)2D3 on ex vivo
PBMC stimulated wi Gram-positive (pneumococci) or Gram-negative (LPS) bacterial ligands.
In this study, we found that pre- reatment with 1,25(OH)2D3 reduced the levels of TN -α, IFN-γ, IL-1β,
and IL-8 in PBMC supernatants in response to heat-killed p eum occal serotype 19F (HK19F) and
LPS stimulation, while only TNF-α and IL-1β were reduced in monocytes.
These results support and extend the broader findings of 1,25(OH)2D3 inhibition of Th1 cytokine
production during inflammation [20–23]. Both 1,25(OH)2D3 and 25(OH)D3 modulated cytokine
responses of both PBMCs and purified monocytes, attributed to CYP27B1 expression on monocytes,
macrophages and dendritic cells (DCs) that convert 25(OH)D3 into its functionally active form [24].
In monocytes, binding of 1,25(OH)2D3-activated VDR/retinoic X receptor (RXR) heterodimer to
vitamin D response elements leads to modulation of key early response immune genes such as CD14
and IL-10, supporting its antimicrobial effects [25,26]. We used HK19F to mimic pneumococcal
infection as serotype 19F is one of the most common serotypes that colonise children in developing
countries, and is also a vaccine serotype [27]. Pneumococci HK19F represents the intact organism
which signals through TLR2 and TLR4, respectively [28–30]. Other studies that used peptidoglycan
from a non-encapsulated S. pneumoniae strain may not r flect tru in vivo responses [19].
ipopolysaccharide was also used to charac e ise pathogen specificity of vitamin D since
25(OH)D3 was previo sly shown to reduce cytokine levels n response to LPS, but not Pam3Cys (TLR2
ligand) [21]. Int restingly, IL-10, a regulatory cytokine, was incre sed by 1,25(OH)2D3 following HK19F
but not LPS stimulation, suggesting a differential impact between these bacterial ligands. This effect
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for HK19F is noteworthy since excessive inflammation can lead to dissemination of pneumococci to
sterile sites in the body as well as facilitate increased transmission [31,32]. Indeed, sustained high
levels of TNF-α, IL-6 and IFN-γ are associated with increased disease severity during pneumococcal
pneumonia [33]. The ability of 1,25(OH)2D3 to control inflammation through IL-10 is intriguing,
and is consistent with its reported anti-inflammatory effects [34–38] and ability to induce functional
regulatory T cells (Treg) [39,40]. Our data suggest this may be due to an increased CD14 expression
although our small sample size limit the significance of this finding. Other reports have demonstrated
that 1,25(OH)2D3 can skew DC-mediated T cell responses from an inflammatory Th1/Th17 phenotype
to an anti-inflammatory Treg phenotype [19], possibly via epigenetic reprogramming [41]. This has
relevance for enteric bacterial infections given the high proportion of Treg found in mucosal tissues [42]
and that 25(OH)D3 deficiency is associated with low IL-10 levels [43]. Further studies on the role of
vitamin D on Treg frequency and function are needed given their anti-inflammatory role.
The anti-inflammatory effects of 1,25(OH)2D3 were supported by our ex vivo data for HK19F
where vitamin D-insufficient individuals had significantly higher IFN-γ than those who were sufficient,
consistent with earlier data [44–46]. Down-regulation of pattern recognition receptor expression
on innate immune cells by 1,25(OH)2D3 would be advantageous in the control of an excessive
inflammatory environment [47]. However, during the initial stages of infection, 1,25(OH)2D3 may
protect against bacterial infections by augmenting CD14 expression, as shown by our data from
LPS-stimulated PBMCs. It has been shown that 1,25(OH)2D3 acts in a paracrine manner with human
epithelial cells by up-regulating IL-1β secretion in Mycobacterium tuberculosis-infected macrophages [48].
Importantly, while vitamin D can dampen inflammatory responses, it does not seem to negatively
impact protective immunity, since individuals with high plasma vitamin D levels (i.e., 25(OH)D)
exhibited normal or enhanced responses to common bacterial and viral vaccines [49–51]. The vitamin
D-VDR signal is also critical for T cell activation [52], providing a possible explanation for the increased
ex vivo CD4 expression observed in our study.
We also found that 1,25(OH)2D3 reduces the migration capacity of neutrophils to casein,
a well-characterised chemoattractant, demonstrating that 1,25(OH)2D3 can exert its effects on multiple
cell targets critical for controlling inflammation [53,54]. It is known that 1,25(OH)2D3 enhances
antimicrobial activity via interaction with VDR to up-regulate the synthesis of antimicrobial peptides
such as cathelicidin and β-defensin [55,56]. Cathelicidin is produced by neutrophils, monocytes,
and macrophages and has broad antimicrobial activity against bacteria, as well as viruses, such
as respiratory syncytial virus (RSV) [57,58]. Moreover, under subclinical inflammatory conditions,
vitamin D may be less able to control inflammatory responses in otherwise healthy individuals [59].
Further elucidation of these complex mechanisms are needed to understand how to harness these
beneficial effects of vitamin D in humans.
Evidence for these effects of vitamin D from larger clinical settings has not been conclusive.
Epidemiologic studies demonstrate strong associations between seasonal variations in 25(OH)D levels
and influenza infection [10], as well as response to vaccines as a result of variable VDR expression
profiles [60–62]. Elevated C-reactive protein as a marker of inflammation was inversely associated
with 25(OH)D deficiency in newborns born in winter–spring, supporting this seasonal effect [63].
Moreover, dysbiosis of the microbiome and susceptibility to infection can be shaped by 25(OH)D
status, further illustrating the biological importance of this molecule in maintaining health [64,65].
However, translating these findings to clinical trials of 1,25(OH)2D3 supplementation in infants and
adults have not been promising largely due to the inconsistency among trial designs. Therefore,
standardisation between clinical trials is critical to elucidate the role of 1,25(OH)2D3 in protection
against bacterial infection.
Several limitations of our study need to be addressed. While our cohort of healthy adults had a
spectrum of plasma 25(OH)D levels, we were still able to observe an effect upon 1,25(OH)2D3 treatment.
Studies in known vitamin D (25(OH)D) deficient populations may reveal more potent effects in this
context. Our sample size was relatively small and so further validation in larger clinically-relevant
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settings are needed. The examination of vitamin D to enhance protection during early life should
be a priority, particularly where exposure to sun may be limited and the pathogen burden may be
high. Our results support the continued investigation of vitamin D in randomized controlled trials,
with potential effects having implications for vaccination, as well as development of novel therapies
for infectious disease.
5. Conclusions
This study supports the anti-inflammatory effects of 1,25(OH)2D3 during bacterial infection.
These results have important implications for the role of vitamin D in protection against infectious
disease, particularly in high-risk settings involving low sunlight and increased exposure to pathogenic
microorganisms. Further investigations, particularly in rigorous clinical trials, are required to
understand to elucidate the beneficial effects of vitamin D in this context.
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